ArticleFrontiers in pharmacology2022

Nucleotide-Binding Oligomerization Domain 1/Toll-Like Receptor 4 Co-Engagement Promotes Non-Specific Immune Response Against K562 Cancer Cells.

Samo Guzelj et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.